Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2017-02-07 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Approval granted for group 3 in Parkinsons trial 2 pages 330.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 8 February 2017. It reports the approval to commence treating patients in a Phase IIb clinical trial for Parkinson's disease. The content focuses on clinical trial progress and future plans for product commercialization. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or interim reports. The document is an announcement of a clinical trial milestone rather than a financial or regulatory report. It is not a report publication announcement since it contains substantive information about the trial approval. The document fits best into the category of a general regulatory announcement or company update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2017-02-07 English
Appendix 4C - quarterly 7 pages 663.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2016' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as cash balances and estimated cash outflows for the next quarter. The report references compliance with Listing Rule 4.7B and Australian Accounting Standards. The content is a comprehensive financial report for a quarter, including actual financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2017
2017-01-19 English
US choroid plexus cells patent application published 2 pages 92.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the publication of a US patent application related to their product NTCELL. It includes details about the patent application number, filing dates, and an abstract of the invention. The document also provides background information about the company and its clinical trials but does not contain any financial data, regulatory certifications, or detailed financial reports. It is a specific announcement about intellectual property and patent publication, not a financial report, management change, or other regulatory filing. Given the content and nature, this fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-01-10 English
Group 2 Parkinsons trial patients treatment completed 3 pages 89.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 22 December 2016. It reports on the completion of treatment of patients in a Phase IIb clinical trial for Parkinson's disease, describing clinical trial progress, patient treatment details, and future plans for the trial and product launch. The content is focused on clinical trial updates and company progress rather than financial results, regulatory filings, or management changes. It is not a full financial report, earnings release, or regulatory filing. The document is a corporate announcement providing operational and clinical trial progress information to investors and the market. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into more specific categories like earnings release or annual report.
2016-12-21 English
Amended Appendix 3B 11 pages 719.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Amended Appendix 3B' related to the issuance of new shares by Living Cell Technologies Limited. Appendix 3B is a standard form used in Australian securities regulation to announce new issues of securities and applications for quotation of additional securities. The content includes details about the number of shares issued, issue price, purpose of the issue, and compliance with ASX rules. There are no financial statements or detailed financial analysis present, only regulatory disclosure about a capital raising event. This fits the category of a Capital/Financing Update (CAP) rather than a full financial report or other types of filings. The document length is substantial but the content is focused on the new share issue announcement and related regulatory compliance.
2016-12-20 English
Corporate Governance Statement 12 pages 397.0KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement' and extensively discusses the company's governance practices, board responsibilities, compliance with governance principles, board structure, nomination committee details, diversity policies, and performance evaluations. It references compliance with the ASX Corporate Governance Council's Principles and Recommendations, and includes detailed disclosures about board roles, committees, and governance policies. There is no indication of financial statements, audit opinions, earnings data, or other financial report content. The document is a detailed governance report rather than an announcement or a brief summary. Therefore, it fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2016-12-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.